Albany, NY -- (SBWIRE) -- 10/19/2018 -- The increasing attempts to cut down the investment of time and capital during research activities in the medical and drug discovery fields are providing a significant momentum to the global DNA chip market. DNA chips play a critical role in aiding medical researchers in measuring the expression levels of thousands of genes at the same time. They are two types, which are oligonucleotide DNA (oDNA) and complementary DNA (cDNA). They are used in gene identification, gene expression profiling, and comparative genomic hybridization.
The research report encompasses all the important parameters of the global DNA chip market, including its dynamics, competitive landscape, and region-wise outlook. The statistics pertaining to the market at both global and regional levels are included in the report. The study profiles key players operating in the market along with their business strategies, latest developments, and contact information.
The growing number of deaths due to cancer every year is creating a pressing need for early cancer detection. According to the American Cancer Society, by 2030, the number of new cancer cases is expected to reach 21.7 million and cancer deaths to 13 million. Therefore, the alarming rate of increase in prevalence is working in favor of the global DNA chip market. Moreover, the spiraling demand for personalized medicines is translating into the greater uptake of DNA chips. The growing investments by governments for research and development in the field are also stoking the growth of the market.
However, the dearth of workforce with adequate technical and clinical acumen is adversely affecting the growth of the global DNA chips market. On the other hand, market players are relocating manufacturing facilities to emerging countries to maximize their revenue generation.
Request to View Brochure of Report -
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4310
The key segments analyzed in the report in terms of geography are North America, Europe, Latin America, Asia Pacific, and the Middle East and Africa. North America will be a prominent market for DNA chip in the coming years. Rapid clinical advancements in the field in the region are providing a tremendous boost to the growth of the market. However, the regional market is poised to reach maturity in the offing and therefore, register a sluggish growth rate.
Asia Pacific, on the other hand, is estimated to expand at an aggressive growth rate during the review period. The growing investments by governments and private organizations in the development of DNA chips are driving the growth of the region. Moreover, the increasing number of clinical trials and drug discovery is fuelling the growth of APAC. Countries such as India, South Korea, Singapore, and China are major revenue contributors to the growth of the region. Among these, Singapore will be at the forefront, owing to the excellent logistics connectivity and supply chain and strong intellectual property laws.
Key players in the global DNA chip market are relying on extensive research and development activities to stay ahead. The growing popularity of DNA chips is attracting new players to venture into this market, which is likely to intensify the competition in the market in the near future. The majority of players are aiming at capitalizing on regions that offer a strong supply chain, cutting-edge scientific infrastructure, skilled manpower, and superior logistical connectivity.
Request to View ToC of the report -
https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=4310
Some of the prominent companies operating in the global DNA chip market are Agilent Technologies, Affymetrix Inc., Eurofins MWG Operon, Biometrix Technology Inc, Biomérieux SA, Bioneer Corporation, Illumina Inc., Greiner Bio-One, Macrogen Inc, Microarrays Inc, Scienion AG, Wafergen Biosystems Inc., Savyon Diagnostics Ltd, Sigma-Aldrich, Life Technologies Corporation, Roche Nimblegen Inc, and Sequenom Inc.